Improved T cell expansion using closed, automatic stirred-tank bioreactors and CTS OpTmizer Pro SFM

In addition to improving the lives of these patients, T Cell therapies possess the potential to address countless other disease states. As such, the T cell therapy market has recently flourished and is expected to grow to $20.3 billion by 2028. In this rapidly expanding field, automation, improved control, and preparation for effective scale-up are critical to the success of these therapies. This has led cell therapy manufacturers to lean heavily on the use of bioreactors for cell expansion, because of their closed and automated design as well as their ability to create an optimal cell environment.

Thank You For Your Interest

First Name *

Last Name *

Business Email *

Business Phone *

Company Name *

Job Title *

Street Address *

City *

Country *

Post Code *

I would like to speak with a Thermo Fisher Scientific technical specialist. *

Please confirm that you would like to receive marketing and promotional email messages about Thermo Fisher Scientific products and services. *

Would you like to receive email updates from The Medicine Maker products, services and events? *

Thermofisher would like to contact you in the future on their products and services via phone, email, and/or post. For more details on our information practices and how to unsubscribe, please see their Privacy Policy. You can unsubscribe at any time.

You have been directed to this site by DemandBytes. For more details on our information practices, please see our Privacy Policy, and by accessing this content you agree to our Terms of Use. You can unsubscribe at any time.

Improved T cell expansion using closed, automatic stirred-tank bioreactors and CTS OpTmizer Pro SFM

Thank You For Your Interest

Accelerating Clean Ammonia Projects and ROI with Digital Solutions